# A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

> **NCT06856200** · NA · RECRUITING · sponsor: **Fudan University** · enrollment: 36 (estimated)

## Conditions studied

- Advanced HR - Positive, HER2 - Negative Breast Cancer
- Resistant to (Neo)Adjuvant Endocrine Therapy

## Interventions

- **DRUG:** Sirolimus (albumin - bound)
- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT06856200
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2025-10
- **Final completion:** 2026-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856200, "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06856200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*